Back to Archived Journals » Oncolytic Virotherapy

Oncolytic Virotherapy ceased publishing in January 2023. All articles that have been published in Oncolytic Virotherapy will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.

Oncolytic Virotherapy

ISSN: 2253-1572


Journal Articles:

- 70 records -

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment

Nguyen HM, Saha D

Oncolytic Virotherapy 2021, 10:1-27

Published Date: 24 February 2021

Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib

Ashton LV, Graham B, Afzali MF, Gustafson D, MacNeill AL

Oncolytic Virotherapy 2020, 9:17-29

Published Date: 26 May 2020

Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development

Jayawardena N, Poirier JT, Burga LN, Bostina M

Oncolytic Virotherapy 2020, 9:1-15

Published Date: 6 March 2020

Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus

Burton C, Bartee MY, Bartee E

Oncolytic Virotherapy 2019, 8:57-69

Published Date: 9 December 2019

Virus–Receptor Interactions: Structural Insights For Oncolytic Virus Development

Jayawardena N, Burga LN, Poirier JT, Bostina M

Oncolytic Virotherapy 2019, 8:39-56

Published Date: 29 October 2019

Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

Zainutdinov SS, Kochneva GV, Netesov SV, Chumakov PM, Matveeva OV

Oncolytic Virotherapy 2019, 8:9-26

Published Date: 12 July 2019

A cautionary note on the selectivity of oncolytic poxviruses

Tang B, Guo ZS, Bartlett DL, Liu J, McFadden G, Shisler JL, Roy EJ

Oncolytic Virotherapy 2019, 8:3-8

Published Date: 11 February 2019

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]

Babiker HM, Riaz IR, Husnain M, Borad MJ

Oncolytic Virotherapy 2019, 8:1-2

Published Date: 4 January 2019

Development and applications of oncolytic Maraba virus vaccines

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD

Oncolytic Virotherapy 2018, 7:117-128

Published Date: 26 November 2018

Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme

Burton C, Das A, McDonald D, Vandergrift III WA, Patel SJ, Cachia D, Bartee E

Oncolytic Virotherapy 2018, 7:107-116

Published Date: 19 November 2018

Oral poliovirus vaccine-induced programmed cell death involves both intrinsic and extrinsic pathways in human colorectal cancer cells

Zhand S, Hosseini SM, Tabarraei A, Saeidi M, Saghaeian Jazi M, Kalani MR, Moradi A

Oncolytic Virotherapy 2018, 7:95-105

Published Date: 30 October 2018

Three-dimensional tumor cell cultures employed in virotherapy research

Kloker LD, Yurttas C, Lauer UM

Oncolytic Virotherapy 2018, 7:79-93

Published Date: 5 September 2018

Oncolytic virus and PD-1/PD-L1 blockade combination therapy

Chen CY, Hutzen B, Wedekind MF, Cripe TP

Oncolytic Virotherapy 2018, 7:65-77

Published Date: 31 July 2018

Current understanding of reovirus oncolysis mechanisms

Phillips MB, Stuart JD, Rodríguez Stewart RM, Berry JTL, Mainou BA, Boehme KW

Oncolytic Virotherapy 2018, 7:53-63

Published Date: 14 June 2018

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer

Nguyen TV, Crosby CM, Heller GJ, Mendel ZI, Barry ME, Barry MA

Oncolytic Virotherapy 2018, 7:43-51

Published Date: 3 May 2018

Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies

Xu C, Goß AV, Dorneburg C, Debatin KM, Wei J, Beltinger C

Oncolytic Virotherapy 2018, 7:37-41

Published Date: 30 April 2018

Oncolytic virotherapy in upper gastrointestinal tract cancers

Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ

Oncolytic Virotherapy 2018, 7:13-24

Published Date: 23 March 2018

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ

Oncolytic Virotherapy 2017, 6:39-49

Published Date: 8 November 2017

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity

Hotta Y, Kasuya H, Bustos I, Naoe Y, Ichinose T, Tanaka M, Kodera Y

Oncolytic Virotherapy 2017, 6:31-38

Published Date: 13 March 2017

Proinflammatory response induced by Newcastle disease virus in tumor and normal cells

Ginting TE, Suryatenggara J, Christian S, Mathew G

Oncolytic Virotherapy 2017, 6:21-30

Published Date: 3 March 2017

Editorial announcing PubMed indexing of Oncolytic Virotherapy

Farassati F

Oncolytic Virotherapy 2017, 6:19-20

Published Date: 15 February 2017

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma

Babiker HM, Riaz IB, Husnain M, Borad MJ

Oncolytic Virotherapy 2017, 6:11-18

Published Date: 9 February 2017

Novel oncolytic viral therapies in patients with thoracic malignancies

Ahmad Z, Kratzke RA

Oncolytic Virotherapy 2017, 6:1-9

Published Date: 21 December 2016

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter

Bhatia S, O’Bryan SM, Rivera AA, Curiel DT, Mathis JM

Oncolytic Virotherapy 2016, 5:99-113

Published Date: 11 November 2016

Oncolytic virotherapy for pediatric malignancies: future prospects

Waters AM, Friedman GK, Ring EK, Beierle EA

Oncolytic Virotherapy 2016, 5:73-80

Published Date: 11 August 2016

Myxoma virus therapy of human embryonal rhabdomyosarcoma in a nude mouse model

Kinn VG, Hilgenberg VA, MacNeill AL

Oncolytic Virotherapy 2016, 5:59-71

Published Date: 8 August 2016

Oncolytic adenovirus-mediated therapy for prostate cancer

Sweeney K, Halldén G

Oncolytic Virotherapy 2016, 5:45-57

Published Date: 14 July 2016

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy

Guan M, Ma Y, Shah SR, Romano G

Oncolytic Virotherapy 2016, 5:35-43

Published Date: 21 June 2016

Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy

Al-Shammari AM, Rameez H, Al-Taee MF

Oncolytic Virotherapy 2016, 5:27-34

Published Date: 20 April 2016

High-throughput screening to enhance oncolytic virus immunotherapy

Allan KJ, Stojdl DF, Swift SL

Oncolytic Virotherapy 2016, 5:15-25

Published Date: 5 April 2016

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Simpson GR, Relph K, Harrington K, Melcher A, Pandha H

Oncolytic Virotherapy 2016, 5:1-13

Published Date: 6 January 2016

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Sokolowski NAS, Rizos H, Diefenbach RJ

Oncolytic Virotherapy 2015, 4:207-219

Published Date: 25 November 2015

Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art

Nande R, Howard CM, Claudio PP

Oncolytic Virotherapy 2015, 4:193-205

Published Date: 25 November 2015

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy

Nakashima H, Nguyen T, Chiocca EA

Oncolytic Virotherapy 2015, 4:183-191

Published Date: 20 November 2015

Targeting tumor vasculature through oncolytic virotherapy: recent advances

Toro Bejarano M, Merchan JR

Oncolytic Virotherapy 2015, 4:169-181

Published Date: 11 November 2015

Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology

Ramírez M, García-Castro J, Melen GJ, González-Murillo A, Franco-Luzón L

Oncolytic Virotherapy 2015, 4:149-155

Published Date: 14 October 2015

Oncolytic Sendai virus-based virotherapy for cancer: recent advances

Saga K, Kaneda Y

Oncolytic Virotherapy 2015, 4:141-147

Published Date: 1 October 2015

Oncolytic virotherapy for human malignant mesothelioma: recent advances

Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF

Oncolytic Virotherapy 2015, 4:133-140

Published Date: 10 September 2015

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor

Sakr HI, Coleman DT, Cardelli JA, Mathis JM

Oncolytic Virotherapy 2015, 4:119-132

Published Date: 4 September 2015

Advances in the design and development of oncolytic measles viruses

Hutzen B, Raffel C, Studebaker AW

Oncolytic Virotherapy 2015, 4:109-118

Published Date: 27 August 2015

Oncolytic virotherapy for head and neck cancer: current research and future developments

Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM

Oncolytic Virotherapy 2015, 4:83-93

Published Date: 20 July 2015

Promising oncolytic agents for metastatic breast cancer treatment

Cody JJ, Hurst DR

Oncolytic Virotherapy 2015, 4:63-73

Published Date: 3 June 2015

More articles